Skip to main content

Table 2 Results of the mixed-effect model

From: Management and treatment outcomes of rheumatoid arthritis in the era of biologic and targeted synthetic therapies: evaluation of 10-year data from the KURAMA cohort

 

DAS28-CRP

CDAI

HAQ

Estimate

Std. error

z value

Pr( >|z|)

Estimate

Std. error

z value

Pr( >|z|)

Estimate

Std. error

z value

Pr( >|z|)

(Intercept)

 − 1.623

2.914

 − 0.557

0.57761

142.9

15.8

9.048

 < 0.0001

31.03

3.191

9.725

 < 0.0001

year

0.000827

0.00145

0.57

0.5684

 − 0.0715

0.00787

 − 9.083

 < 0.0001

 − 0.0157

0.0016

 − 9.831

 < 0.0001

Age

0.00126

0.00052

2.416

0.01571

0.00616

0.00319

1.932

0.05335

0.01008

0.00087

11.538

 < 0.0001

Sex

0.01499

0.01745

0.859

0.39008

0.2061

0.1073

1.921

0.05473

0.1302

0.02968

4.388

 < 0.0001

Stage

0.05452

0.00498

10.943

 < 0.0001

0.3038

0.0289

10.512

 < 0.0001

0.06813

0.00638

10.674

 < 0.0001

Class

0.09475

0.00698

13.57

 < 0.0001

0.6173

0.03747

16.476

 < 0.0001

0.1606

0.00738

21.768

 < 0.0001

b/tsDMARDs use

 − 0.0546

0.01083

 − 5.041

 < 0.0001

 − 0.1233

0.06147

 − 2.006

0.04485

0.05008

0.01282

3.908

 < 0.0001

dose_MTX

0.00366

0.00121

3.036

0.0024

0.02375

0.00676

3.511

0.00045

3.6E − 05

0.00138

0.026

0.97893

dose_GC

0.00346

0.00102

3.389

0.0007

0.01246

0.0054

2.309

0.02096

0.00156

0.00099

1.579

0.11423

BMI

0.00369

0.00165

2.235

0.02544

0.00605

0.00969

0.625

0.53224

 − 0.0008

0.00223

 − 0.363

0.71695

RF

9.5E − 05

1.6E − 05

5.763

 < 0.0001

0.00047

9E − 05

5.252

 < 0.0001

5.9E − 05

1.8E − 05

3.385

0.00071

ACPA

3.3E − 05

1.2E − 05

2.782

0.0054

0.0001

6.6E − 05

1.569

0.11676

1E − 05

1.3E − 05

0.777

0.43714

  1. DAS28-CRP Disease Activity Score 28-C-reactive protein, CDAI Clinical Disease Activity Index, HAQ Health Assessment Questionnaire Disability Index, RF rheumatoid factor, ACPA anti-citrullinated protein antibody, MTX methotrexate, GC glucocorticoid, b/tsDMARDs biologic or targeted synthetic disease-modifying antirheumatic drugs, BMI body mass index